Keiding Hans, Hildebrandt Per, Burke Thomas, Carides George W
Københavns Universitet, Økonomisk Institut, H:S Frederiksberg Hospital, Kardiologisk-endokrinologisk Klinik E, København K.
Ugeskr Laeger. 2006 Oct 16;168(42):3623-6.
The purpose of this analysis was to evaluate the cost-effectiveness of losartan compared with atenolol for the treatment of hypertension, both from the point of view of society and from that of the health care sector, based on data from the LIFE study.
The computations are based on a simple decision tree model, where the probability of stroke was obtained from the LIFE study, a double-blind, randomised clinical study of 9,193 patients with hypertensive left ventricle hypertrophy.
The treatment of hypertension with losartan rather than atenolol entails a cost of DKK 19,668 per gained quality-adjusted life year (QALY), when only the cost of the health care sector is taken into account, and DKK 72,564 if all costs to society are included.
The analysis shows that treatment with losartan is cost-effective even when the uncertainty in both data and economic evaluations is taken into account.
本分析的目的是基于LIFE研究的数据，从社会和医疗保健部门的角度评估氯沙坦与阿替洛尔治疗高血压的成本效益。
计算基于一个简单的决策树模型，其中中风概率来自LIFE研究，这是一项对9193例高血压左心室肥厚患者进行的双盲随机临床研究。
仅考虑医疗保健部门的成本时，用氯沙坦而非阿替洛尔治疗高血压每获得一个质量调整生命年（QALY）的成本为19668丹麦克朗；若将社会的所有成本都包括在内，则为72564丹麦克朗。
该分析表明，即使考虑到数据和经济评估中的不确定性，用氯沙坦治疗仍具有成本效益。
